Company Press Releases (Prior to 2016) 4 Dec 2013 FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds 26 Feb 2015 FLAG Therapeutics Announces The Issuance Of A New U.S. Patent That Includes Composition Of Matter On Their Bi-Specific Lead Candidate For Oncology 25 Mar 2015 FLAG Therapeutics Awarded A North Carolina Biotechnology Center Small Business Research Loan To Advance Its Lead Oncology Drug 10 Mar 2015 FLAG Therapeutics Announces Patent Issuance for Bi-Specific, Folate Receptor Alpha Targeted Inhibition in Cancerous Tumors
